BioSpace News Archive

Children with Dravet syndrome, a severe form of epilepsy that begins in infancy, experience seizures, usually for their entire life.

MDxHealth SA announced its financial results for the first quarter ended March 31, 2022.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s first quarter 2022 financial results on Wednesday, May 4, 2022 after the close of U.S. financial markets.

Rapid rise in remote patient monitoring amid the COVID-19 pandemic, increasing use of wearable medical devices for efficient monitoring and provision of timely treatment, and availability of cost-effective IoT healthcare devices are some key factors expected to drive market growth.

Clarus Therapeutics Holdings, Inc. announced the closing of its previously announced underwritten public offering of units consisting of 26,680,720 shares of its common stock and accompanying Class A warrants to purchase up to 26,680,720 shares of its common stock and units consisting of pre-funded warrants to purchase up to 590,000 shares of common stock and accompanying Class A warrants to purchase up to 590,000 shares of common stock.

The U.S. Food and Drug Administration issued draft action levels for lead in single-strength apple juice and other single-strength juices and juice blends.

ResMed announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Tuesday, May 3, 2022, beginning at approximately 8:45 a.m. via video webcast.

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Biomea Fusion, Inc. announced the acceptance of two abstracts at the 2022 American Society of Clinical Oncology Annual Meeting.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted nine employees nonqualified stock options to purchase an aggregate of 42,550 shares of its common stock with an exercise price of $3.17, which is equal to the closing price of Gritstone’s common stock on April 21, 2022, the grant date of the awards.